Swiss drugmakers Roche and Novartis underscored how their portfolios are increasingly clashing on the commercial battlefield, announcing new data on drugs aimed at capturing market share from each other.
Indivior Plc raised the company’s full-year 2019 forecasts as the embattled British drugmaker’s best-selling opioid addiction drug Suboxone fared better than expected in the face of competition from copycats.
Despite numerous FDA approvals of biosimilars, they have not yet gained a significant stake in the U.S. marketplace, according to a recent analysis published in Forbes.
Eli Lilly and Co.’s migraine treatment Emgality became the first drug to gain U.S. approval for decreasing the frequency of episodic cluster headache attacks.